At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed stage IV breast cancer with stable or progressive disease after therapy
- ✓Measurable disease: ≥20 mm with conventional imaging or ≥10 mm with spiral CT
- ✓Prior treatment: 1-2 conventional chemotherapy regimens for metastatic breast cancer; unlimited prior hormonal or immunotherapy; if HER2+ prior trastuzumab required
- ✓ECOG performance status ≤2 (Karnofsky ≥60%)
- ✕Any prior EGFR-targeting therapy (e.g., ZD1839, C225)
- ✕Any prior VEGF/KDR inhibitors (e.g., VEGF Trap, Su5416, Su6668, ZD6474, PTK757, IMC-1CII)
- ✕CNS disease including brain metastases, primary brain tumor, uncontrolled seizures, or history of stroke
- ✕Corneal abnormalities (dry eye, Fuch's dystrophy, abnormal slit-lamp exam, or abnormal Schirmer test)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Erlotinib Hydrochloride, and 1 other intervention for Recurrent Breast Carcinoma and Stage IV Breast Cancer. Completed, enrolled 38 participants across 2 sites.
Detailed Summary
This phase II trial studies how well erlotinib hydrochloride and bevacizumab work in treating patients with stage IV breast cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving erlotinib hydrochloride and bevacizumab may be an effective treatment for breast cancer.
Study Details
Timeline
Interventions
Given IV
Given PO
Correlative studies